Abstract
Introduction
The dogma for treatment of cancer has changed, with the cytotoxic drugs used
in chemotherapy regimes set to lose their dominance and be used alongside
targeted therapies that are being developed with the aim of more specifically
targeting cancer cells
Research and analysis highlights
In this comprehensive report covering targeted therapies in oncology,
BioSeeker Group has analyzed apoptopic agents, protein kinase inhibitors,
anti-angiogenic and vascular targeting agents, immunostimulators, antibodies
and vaccines in oncology. This extensive 550+ pages report compiles and
analyzes in parallel the progress concerning drug development and competitive
situation in the mentioned key oncology targeted therapy areas. The report
will not only provide a framework but also a careful identification and
evaluation of drug candidates, technologies and competitors. The number of
targeted therapy drugs has risen sharply, as have the number of targets. The
fiercest competition in oncology targeted therapy is pointed out and how
several big pharma companies are out hunting for promising technology and
drugs to complement their internal pipeline.
Scope of this report
- In-depth competitive landscape assessment of the targeted oncology market
place; Including more than 340 drugs and pharmaceutical companies
- Thorough review of six major targeting strategies in oncology: Apoptopic
agents, Protein kinase inhibitors, Anti-angiogenic and vascular targeting
agents, Immunostimulators, Antibodies and Vaccines
- Progress analysis of major cancer indications for respective targeting
strategy, including players, drugs, clinical progress and pitfalls
- Includes more than 120 Tables, 60 Boxes and close to 40 Figures
Key reasons to read this report
- Understand the clinical and strategic challenges to the commercialization
of six major targeting strategies in oncology
- Assess opportunities and risks for the continued development of targeting
agents in major cancer indications.
- Adopt knowledge from this analysis to drive strategic planning decisions
in oncology drug development
| 
View Cart
